NCT00573469 - Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Crohn's Disease

Interventions

DRUG

D9421-C, 9mg

D9421-C 9 mg was given once daily for 8 weeks.

DRUG

D9421-C, 15mg

D9421-C 15 mg was given once daily for 8 weeks.

DRUG

Placebo

D9421-C matching placebo was given once daily for 8 weeks.

Trial Locations (22)

Research Site, Nagoya

Research Site, Sakura

Research Site, Chikushino-shi

Research Site, Fukuoka

Research Site, Kurume

Research Site, Hashima-gun

Research Site, Fukuyama

Research Site, Hiroshima

Research Site, Asahikawa

Research Site, Sapporo

Research Site, Kobe

Research Site, Kyoto

Research Site, Ōita

Research Site, Kurashiki

Research Site, Osaka

Research Site, Suita

Research Site, Tokorozawa

Research Site, Shinjuku-ku

Research Site, Toyama

Research Site, Itami

Research Site, Nishinomiya

Research Site, Tokyo